India
oi-Madhuri Adnal
New Delhi, June 23: Yoga guru Ramdev-run Patanjali Ayurved on Tuesday launched Coronil, an Ayurvedic medicine, to help treat the novel coronavirus or Covid-19 infection on Tuesday at Patanjali Yogpeeth in Haridwar, Uttarakhand.
Launch of first and foremost evidence-based ayurvedic medicine for Covid-19@yogrishiramdev @Ach_Balkrishna #Patanjali #आयुर्वेदविजय_कोरोनिल_श्वासारि pic.twitter.com/3hiyUSnZJX
— Patanjali Ayurved (@PypAyurved) June 23, 2020
According to reports, Baba Ramdev had revealed that COVID-19 patients who were given Coronil – which is made from a mixture of Ashwagandha, Giloy and Tulsi – showed 100 per cent recovery rate.
#आयुर्वेदविजय_कोरोनिल_श्वासारि#कोरोना की एविडेंस बेस्ड प्रथम #आयुर्वेदिक औषधि, #श्वासारि_वटी ,#कोरोनिल का संपूर्ण साइंटिफिक डॉक्यूमेंट के साथ #पतंजलि योगपीठ हरिद्वार से पूज्य @yogrishiramdev जी और पूज्य @Ach_Balkrishna जी का 12 बजे लॉन्चिंग व लाइव प्रेस वार्ता pic.twitter.com/LMU7FnZaos
— Patanjali Ayurved (@PypAyurved) June 23, 2020
Patanjali’s Chief Executive Officer (CEO), Acharya Balkrishna, had earlier claimed that the company has found a cure for was able to cure at least 1,000 coronavirus patients within 5-14 days.
According to the company they have conducted ‘randomized placebo-controlled clinical trials’ and during the conference, they will reveal the outcome of the test.
“We appointed a team of scientists after the Covid-19 outbreak. First, the simulation was done and compounds were identified which can fight the virus and stop its spread in the body. Then, we conducted a clinical case study on hundreds of positive patients and we have got 100 per cent favourable results. We are not talking about an immunity booster. We are talking about a cure,” Patanjali CEO Acharya Balkrishna said in Haridwar, according to ANI.
Apart from Patanjali, three other drugs were launched by Indian pharma companies for emergency care of Covid-19 patients. On Saturday Glenmark Pharmaceuticals launched the antiviral drug Favipiravir under the name Fabiflu, and it was followed by the launch of the anti-viral drug Remdesivir by pharma companies Cipla and Hetero under the brand name Cipremi and Covifor respectively.
